

# New Company Life Science Opportunities

Q1 2024



# Fundraising Companies



# Abcon Therapeutics



- Field: T-cell mediated diseases and related cancers, with initial focus on T-Cell Lymphoma (TCL).
- Mode and MOA: First product, ATX101, is a fully humanized monoclonal antibody-drug conjugate (ADC) that targets CD6, an established T-Cell specific receptor.
- Data: ATX101 has been highly effective in treating preclinical models of TCL, demonstrating tumor shrinkage and inhibition of tumor metastasis.
- Current development status: IND-enabling tox studies.
- IP: Exclusive license to CCF-developed mAbs and ADCs; Issued and pending patent applications covering composition of matter and methods of treating T-cell mediated disease.
- Raise: Active Series A Round.

# Mobius Care



- Field: Inflammatory bowel disease (IBD).
- Mode and MOA: Novel AI digital pathology tool for stratification of IBD patients to existing drugs and candidates under development.
- Data: In vitro and in vivo proof of concept established.
- Current development status: In vivo validation.
- IP: Exclusive option to CCF - and Washington University-developed intellectual property; Pending patent applications covering diagnostic methodologies.
- Raise: Active Seed Round.



# Neurotherapia



- Field: Neuroinflammation for CNS disease; initially targeting Alzheimer's Disease (AD).
- Mode and MOA: Small molecule therapies targeting microglial cells; Lead compound NTRX-07 is a CB2 agonist shown to reduce neuro-inflammation.
- Data: Phase 1 safety studies in AD completed successfully.
- Current development status: Ready for phase 2 clinical studies.
- IP: Exclusive license to CCF-developed small molecules; Issued and pending patent applications covering composition and method of use for treating neuroinflammation.
- Raise: Active Series A Round.



# Zehna Therapeutics




- Field: Cardiometabolic diseases with initial focus on cardiovascular disease (CVD) and chronic kidney disease (CKD).
- Mode and MOA: Small molecules inhibit gut microbial enzyme CutC, preventing molecular conversion to trimethylamine N-oxide (TMAO) – a metabolite connected to CVD and CKD risk.
- Data: In vivo proof-of-concept established.
- Current development status: Expect IND-ready in 2024.
- IP: Exclusive license to CCF-developed small molecules; Issued and pending patent applications covering compositions and methods of use.
- Raise: Active Series A Round.

# Co-Creation Opportunities



# PSMA

- Field: Radiotheranostics for treatment of prostate cancer.
- Mode and MOA: Next-generation PSMA-targeting radioligand has higher specificity than on-market prostate cancer radiotherapies, reducing side effects.
- Data: In vivo proof-of-concept established.
- Current development status: GMP manufacturing completed and released under CoA; IND-enabling stability and acute toxicity studies in progress; Phase 0 study ready expected 2024.
- IP: Exclusive option to CCF-developed compounds; Issued and pending patent applications covering compositions and methods of use.
- Ask: Seeking co-investment or co-development partners.





# ComAb

- Field: Complement-mediated diseases.
- Mode and MOA: Pipeline of monoclonal antibody (mAb) therapeutics targeting various aspects of the complement cascade; lead programs targeting C6, a key protein in membrane attack complex (MAC) formation.
- Data: In vivo proof-of-concept established.
- Current development status: Lead program fully humanized and entering IND-enabling studies.
- IP: CCF has filed patent applications covering compositions and methods of use.
- Ask: Seeking co-investment or co-development partners.



# *Partner* with us

Impactful alliances are at the heart of our mission to transform brilliant ideas into life-changing healthcare solutions.

## License technologies



## Build strategic partnerships



## Invest



[clevelandclinic.org/innovations](https://clevelandclinic.org/innovations)



[innovations@ccf.org](mailto:innovations@ccf.org)  
216.444.5757





**Every life deserves world class care.**